FDA Approves Better Therapeutics’ Prescription Digital Behavioral Treatment For Type 2 Diabetes

The U.S Food and Drug Administration (FDA) approved a prescription digital therapeutic (PDT) behavioral treatment developed by Better Therapeutics, Inc., for adults with type 2 diabetes (T2D). The PDT, AspyreRx™, provides cognitive behavioral therapy. Better Therapeutics anticipates the commercial launch of AspyreRx in the fourth quarter of 2023. No proposed reference price has been announced.

AspyreRx (formerly BT-001) is Better Therapeutics’ clinically validated prescription digital therapy for the treatment of T2D. Using proven techniques that target the underlying psychological, behavioral and cognitive factors that sustain or worsen T2D, AspyreRx is a self-paced, engaging experience that patients can . . .